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Validation of a Predictive Model for Survival in Patients With 
Advanced Cancer: Secondary Analysis of RTOG 9714
Edward Chowa, k, Jennifer L. Jamesb, William Hartsellc, Charles W. Scarantinod, 
Robert Ivkere, Mack Roach, IIIf, John H. Suhg, William Demash, 
Andre Konskii, Deborah Watkins Brunerj
Abstract
Background: The objective of this study was to validate a simple 
predictive model for survival of patients with advanced cancer.
Methods: Previous studies with training and validation datasets 
developed a model predicting survival of patients referred for pal-
liative radiotherapy using three readily available factors: primary 
cancer site, site of metastases and Karnofsky performance score 
(KPS). This predictive model was used in the current study, where 
each factor was assigned a value proportional to its prognostic 
weight and the sum of the weighted scores for each patient was sur-
vival prediction score (SPS). Patients were also classifi ed accord-
ing to their number of risk factors (NRF). Three risk groups were 
established. The Radiation Therapy and Oncology Group (RTOG) 
9714 data was used to provide an additional external validation set 
comprised of patients treated among multiple institutions with ap-
propriate statistical tests. 
Results: The RTOG external validation set comprised of 908 pa-
tients treated at 66 different radiation facilities from 1998 to 2002. 
The SPS method classifi ed all patients into the low-risk group. 
Based on the NRF, two distinct risk groups with signifi cantly dif-
ferent survival estimates were identifi ed. The ability to predict 
survival was similar to that of the training and previous validation 
datasets for both the SPS and NRF methods.
Conclusions: The three variable NRF model is preferred because 
of its relative simplicity.
Keywords:  Survival prediction; Advanced cancer
Introduction
Survival prediction of patients with advanced cancer is one 
of the most diffi cult and least welcomed tasks clinicians 
have to face. However such an estimate is very important in 
end-of-life care [1]. Inaccurate prediction of survival often 
results in inadequate access to palliative care. Overly opti-
mistic prediction may deter patients from being involved in 
palliative programs at an earlier stage.
Patient preferences about the trade-off between the risks 
and benefi ts associated with treatment strategies are often 
based on perceptions of prognosis. Inaccurate perceptions 
can lead to unrealistic expectations [2]. Weeks and col-
leagues found that patients with a misperceived optimistic 
prognosis often request medical therapies that most physi-
cians would consider futile. These same patients were 8.5 
times more likely to favor receiving aggressive, life-extend-
ing medical care than were patients with more accurate es-
timates of their 6-month survival. More disturbingly, those 
with overly optimistic prognoses were more likely to die in 
hospital on mechanical ventilation than were those patients 
with more realistic estimates of their survival potential. The 
authors conclude that terminal cancer patients’ miscalibrated 
optimistic prognosis may lead them to choose highly aggres-
sive, invasive and ultimately futile medical care rather than 
palliative care [3].
The accurate classifi cation of patients with advanced 
cancer into groups with similar and predictable survival has 
the potential to improve delivery of care and minimize un-
dertreatment or overtreatment [2, 4]. In validating a classi-
fi cation model, there is a hierarchy of increasing stringent 
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validation strategies [5]: 1) Internal – evaluation restricted to 
a single training data set; 2) Temporal – evaluation on a sec-
ond data set at a different time point from the same center; 3) 
External – evaluation on data from a different center, perhaps 
by different investigators. 
We previously developed a predictive model for patients 
with advanced cancer by employing three readily avail-
able parameters: primary cancer site, site of metastases and 
Karnofsky performance score (KPS). The initial classifi ca-
tion model was developed with a training data set (n = 395) 
comprised of patients treated at Sunnybrook Odette Cancer 
Center’s Rapid Response Radiotherapy Program (RRRP) in 
1999. Three risk groups–low, intermediate, high–were de-
termined by partial score method and number of risk factors 
(NRF) method (details in materials and methods section) 
(Table 1) [6, 7]. A temporal validation set (n = 445) of pa-
tients treated in the RRRP in 2000 and an external validation 
set (n = 467) of patients treated at Princess Margaret Hospi-
tal’s Palliative Radiation Oncology Program in 2002 were 
used to successfully evaluate the initial model.
The objective of this secondary study was to use Radia-
tion Therapy Oncology Group (RTOG) 9714 data to provide 
an additional external validation set to the two methods com-
prised of patients treated among multiple institutions in the 
United States and Canada.
Materials and Methods
Patient population
The Radiation Therapy and Oncology Group (RTOG) and 
the North Central Cancer Treatment Group conducted a ran-
domized Phase III trial with breast or prostate cancer patients 
with bone metastases (RTOG 9714) [8]. Eligible patients 
had moderate or severe pain, as indicated by a Brief Pain 
Inventory (BPI) worst pain score of 5 and above or narcotic 
medication with a daily oral morphine equivalent dose of at 
Prognostic Factor Partial Score Method Risk Factor Score Method
Primary tumor site
    Breast 0 0
    Prostate 2 1
    Lung 3 1
    Others 3 1
Site of metastases
    Bone only 0 0
    Other 2 1
KPS
    > 60 0 0
    ≤ 60 3 1
Survival Prediction Score (SPS) determined by 
sum of partial scores
Number of Risk Factors Score (NRF) determined by 
sum of risk factors
Risk Group A [SPS 0 - 4] Risk Group I [NRF 0 - 1]
Risk Group B [SPS 5] Risk Group II [NRF 2]
Risk Group C [SPS 6 - 8] Risk Group III [NRF 3]
Table 1. Risk Groups Previously Identifi ed
Note: Sum of partial scores equal to survival prediction score (range 0 to 8).
KPS: Karnofsky performance score
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Characteristic n (%)
Gender
    Male 447 (49)
    Female 461 (51)
Age (years)
    Mean ± SD 65 ± 12
    Median (range) 67 (31 - 92)
Country of Residence
    Canada 38 (4%)
    USA 870 (96%)
Primary cancer site
    Breast 462 (51)
    Prostate 446 (49)
Karnofsky performance status (KPS)
    40 - 60 214 (24)
    70 - 100 694 (76)
Physician predicted survival time (months)
    Mean ± SD 14.5 ± 14
    Median (range) 12 (1 - 99)
Painful site(s)
    Single 542 (60)
    Multiple 366 (40)
Site of radiotherapy
    Weight bearing 506 (56)
    Non-weight bearing 402 (44)
BPI worst pain score at study entry*
    < 5 with ≥ 60 mg/day morphine 17 (2)
    5 - 6 254 (28)
    7 - 10 637 (70)
Receiving biphosphonates at study entry
    No 688 (76)
    Yes 220 (24)
Radiation treatment assignment
    8 Gy 460 (49)
    30 Gy 448 (51)
Table 2. Patient Characteristics From RTOG Validation Set (N = 908)
*BPI: Brief Pain Inventory
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least 60 mg if pain scores were < 5. Patients were random-
ized between treatment with a single fraction of 8 Gy and 
30 Gy in 10 fractions. The Karnofsky performance status of 
the enrolled patients was at least 40, with an estimated life 
expectancy of at least 3 months. Patients were excluded if 
there was prior radiation therapy or palliative surgery to the 
planned radiation treatment site, pathologic or impending 
fracture, or compression of the spinal cord or cauda equina 
[8]. The survival status and the date of death from any cause 
or last follow up of the patients were current as of February 
2009.
Predictive models
Partial score method (SPS)
A prognostic score (partial score) based on the regression 
coeffi cients of the Cox regression model was assigned to the 
three factors [primary cancer site (breast/prostate/lung/oth-
ers), site of metastases (bone/others), and KPS (> 60/≤ 60)] 
as in the previous work (Table 1) [6]. The survival predic-
tive score (SPS) for a given patient was obtained by add-
ing together his/her partial scores for the three factors [6, 9]. 
Patients were classifi ed into risk groups based on their SPS 
score. Three risk groups A, B and C were established.
Number of risk factors method (NRF)
The patients were also grouped according to the total number 
of risk factors (NRF) that they possessed [6]. The three risk 
factors are as follows: (1) non-breast (i.e., prostate), (2) site 
of metastases other than bone only, and (3) KPS ≤ 60. Three 
risk groups I, II and III were established.
Comparison of risk groups
The logrank test was used to determine differences in overall 
survival in the resultant risk groups. The resultant median 
survival estimates in each risk group were also compared to 
those of the corresponding risk group in the previous datasets 
for similarity. Additional methods were then used to evaluate 
model discrimination. The C index of predictive discrimina-
tion measures the proportion of correct predictions based on 
observed responses. The C index ranges from 0 to 1 with val-
ues of 0.5 indicating no predictive discrimination (random 
classifi cation) between patients with different outcomes and 
values close to 1 indicating perfect discrimination (proper 
classifi cation) [10]. The Royston and Sauerbrei D statistic 
is also a measure of discrimination of the survival model 
based on its ability to separate survival estimates between 
risk groups. Higher values indicate a better degree of model 
Table 3. Derivation of Risk Groups From RTOG Validation Set
*Cox Proportional Hazards Regression Model
Prognostic Factor Parameter Estimate*
Standard 
Error
Hazard Ratio
[95% CI] P-value
Partial 
Score
Risk Factor 
Score
Primary Cancer Site
    Breast 0.00 1.00 0 0
    Prostate 0.42 0.07 1.52 [1.33, 1.74]
< 
0.0001 2 1
Site of metastases
    Bone only -- -- -- -- 0 0
Karnofsky Performance 
Status
    > 60 0.00 0 0
    ≤ 60 0.46 0.08 1.58 [1.35, 1.85]
< 
0.0001 2 1
Survival Prediction Score (SPS) [sum of partial scores] Risk Group A [SPS 0 - 4]
Number of Risk Factors Score (NRF) [sum of risk factors] Risk Group I [NRF 0 - 1]
Risk Group II [NRF 2]
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separation [11].
Results
  
The RTOG external validation set comprised of 908 patients 
treated at 66 different radiation facilities from 1998 to 2002. 
Canadian patients represented only 4% of the patient popu-
lation (Table 2). The mean age was 65 years (SD 12). There 
were slightly more females (51% vs. 49%). Although geo-
graphic variability was obtained, RTOG 9714 had a fairly 
homogenous population in regards to prognostic variables. 
All patients had bone metastases and had either a breast 
(51%) or a prostate (49%) primary tumor, as these disease 
specifi cations were trial eligibility criteria. Only twenty-four 
percent of patients had KPS ≤ 60 as a life expectancy of at 
least 3 months was also a trial eligibility criterion [8].
The SPS method classifi ed all patients into the low-risk 
Group A with scores from 0 - 4 (Table 3). The 3 month sur-
vival estimate for patients in Group A was 84% which was 
comparable to that of the training set at 82% (Table 4). Given 
that there were no identifi ed intermediate/high-risk patients, 
the C index of discrimination was 0.96, indicating near per-
fect model discrimination. 
Based on the NRF, two risk groups were identifi ed. Pros-
tate patients with KPS ≤ 60 were classifi ed into the interme-
diate-risk group II. Eleven percent of patients had those 2 
risk factors. Prostate patients with KPS > 60 and all breast 
patients were classifi ed into the low-risk Group I. Eighty-
nine percent of patients had those 0 - 1 risk factors. The 3 
month survival estimates for patients in Group I and Group II 
were 85% and 72%, respectively, which was comparable to 
that of the training set at 80% and 73%, respectively (Table 
5). Given that there were no identifi ed high-risk patients, the 
C index of discrimination was 0.94, indicating near perfect 
model discrimination. The Royston and Sauerbrei D statistic 
was 0.82, indicating good model discrimination.
Based on these results, the NRF method is preferable to 
the SPS method in that it gives a more accurate classifi cation 
of patients and requires simpler calculation. The NRF meth-
od is able to further distinguish intermediate-risk patients 
that the SPS method classifi es into a low-risk group only. 
The difference in survival estimates of the two classifi cation 
groups was statistically signifi cant (P < 0.0001) (Fig. 1).
Discussion
  
Physicians are often requested to predict patient survival at 
times of referral to hospice programs and enrollment into 
clinical trials [2]. However, clinicians are often overly op-
timistic in the survival prediction of terminally ill cancer 
patients [12, 13]. Parkes, in a commentary, aired his disap-
pointment that doctors are still no better at predicting the 
length of survival of terminally ill patients than they were 
27 years ago. He also stated that if all predictions had been 
divided by two, they would have been marginally more ac-
curate. He urged that prognoses should be based on proven 
Predictive Model
Training Set Temporal Validation Set
External Validation 
Set
[Single Institution]
RTOG External Validation 
Set
[Multiple Institutions]
N = 395 N = 445 N = 467 N = 908
Model Performance
    Harrel C index 0.66 0.65 0.63 0.96
Risk Group A
[Survival Prediction Score, 
0 - 4]
    n (%) 108 (27%) 126 (28%) 65 (14%) 908 (100%)
    Median Survival (weeks) 60 53 64 42
    95% CI [41, 70] [36, 75] [28, undefi ned] [38, 45]
    Survival Probabilities
    3 months 82% 86% 83% 84%
    6 months 70% 72% 64% 66%
    9 months 52% 51% 53% 43%
Table 4. Summary of Model Performance and Survival Estimates: Partial Score Method
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indexes and not intuition. Physicians need to stop guessing, 
and when predictions are needed, they should make use of 
the available predictive instruments [14].
The inaccuracy of survival prediction by palliative ra-
diation oncologists has been well documented. After consul-
tations of cancer patients with metastatic disease for referral 
of palliative radiotherapy, six radiation oncologists provided 
survival estimates for 739 patients. These were compared 
with the actual dates of death obtained from the Cancer 
Death Registry. The prediction of survival by palliative radi-
ation oncologists was inaccurate and tended to be overly op-
timistic [15]. Hartsell et al reported the physician prediction 
of the survival of patients in RTOG 9714. Again the survival 
prediction was optimistic compared to actual survival by an 
average of 3 months. The median survival of the 618 expired 
patients was 6.5 months and the median physician prediction 
of survival was 12 months [16].
Reviews on survival prediction were conducted by Glare 
Table 5. Summary of Model Performance and Survival Estimates: Number of Risk Factors Method
Predictive Model
Training 
Set
Temporal 
Validation Set
External 
Validation Set
[Single Institution]
RTOG External 
Validation Set
[Multiple Institutions]
N = 395 N = 445 N = 467 N = 908
Model Performance
    Harrel C index 0.65 0.66 0.63 0.94
    Royston and Sauerbrei D 
statistic 1.09 1.08 0.84 0.82
Risk Group I
Number of Risk Factors* 
≤ 1
    n (%) 98 (25%) 116 (26%) 64 (14%) 812 (89%)
    Median Survival (weeks) 60 55 64 45
    95% CI [37, 70] [37, 91] [28, undefi ned] [41, 51]
    Survival Probabilities 
    3 months 80% 87% 83% 85%
    6 months 68% 73% 63% 69%
    9 months 53% 54% 53% 46%
Risk Group II
Number of Risk Factors 
= 2
    n (%) 166 (42%) 193 (43%) 189 (40%) 96 (11%)
    Median Survival (weeks) 26 19 28 23
    95% CI [20, 31] [17, 28] [22, 34] [17, 31]
    Survival Probabilities
    3 months 73% 68% 76% 72%
    6 months 51% 45% 52% 46%
    9 months 26% 23% 25% 19%
*Risk factors include prostate primary tumor and KPS ≤ 60.
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et al [17] and the European Association for Palliative Care 
[18]. In a systematic review of physicians’ survival predic-
tion in terminally ill cancer patients, Glare et al evaluated 8 
published studies providing 1563 individual prediction-sur-
vival dyads. Clinical prediction of survival (CPS) was gen-
erally overoptimistic, with the median CPS 42 days and the 
median actual survival (AS) 29 days. The CPS was correct to 
within one week in only 25% of cases and overestimated sur-
vival by at least four weeks in 27%. The survival of patients 
was typically 30% shorter than predicted.
The Steering Committee of the European Association 
for Palliative Care (EAPC) published their evidence-based 
clinical recommendations on the prognostic factors in ad-
vanced cancer patients. In their analysis of the 16 eligible 
studies, the correlation coeffi cient of the CPS and AS varied 
between 0.2 and 0.65. CPS was more than twice as likely to 
be overoptimistic versus overpessimistic and to overestimate 
the length of actual survival by a factor of between 3 and 
5. The committee recommends clinicians should consider 
using CPS in combination with other prognostic factors or 
scores to improve the accuracy of their predictions [18].
The fi rst study investigating a prognostic model in 395 
patients contained six signifi cant covariates: primary cancer, 
site, site of metastases, KPS, fatigue, appetite, and shortness 
of breath [6]. The discrimination C index for this model was 
0.73, 0.75 and 0.81 for discrimination between patients sur-
viving past 3, 6, and 12 months, respectively. 
The subsequent study attempted to simplify this six vari-
able model to include only three factors: primary cancer site, 
site of metastases, and KPS [7]. Utilizing the SPS method, a 
Figure 1. Survival estimates and risk classifi cation group.
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training set, temporal validation set and external validation 
set had C indices of 0.66, 0.65 and 0.63, respectively. Using 
the NRF method, D statistics were listed as 0.65, 0.66, and 
0.63 for the same above three sets, respectively. The patient 
characteristics can be seen in Table 6 for comparison with 
the current validation set. 
This present analysis is limited by the eligibility crite-
ria of RTOG 9714 allowing only breast/prostate primary tu-
mors and KPS > 40, thus limiting the classifi cation ability 
of the original model. We have validated the low risk group 
in SPS model and the low/intermediate risk groups in the 
NRF model but cannot draw conclusions about the high risk 
patients. We encourage other investigators to validate espe-
cially the high risk groups. Until then, as Parkes encourages, 
when predictions are needed, physicians should make use 
of the available validated predictive instruments such as the 
current one.
Studies have been conducted to determine the optimal 
1999, RRRP
(n = 395)
2000, RRRP
(n = 445)
2002, PMH
(n = 468)
Gender N (%) N (%) N (%)
    Male 198 (50%) 243 (56%) 246 (53%)
    Female 197 (50%) 202 (45%) 222 (47%)
Age (years)
    Median 68 69 66
    Range 31 - 93 24 - 93 24 - 91
Primary cancer site
    Lung 143 (36%) 132 (30%) 266 (55%)
    Breast 80 (20%) 99 (22%) 62 (13%)
    Prostate 56 (14%) 70 (16%) 24 (5%)
    Others 116 (30%) 144 (32%) 126 (27%)
Weight loss
    ≥ 10% over the last 6 months 132 (33%) 141 (32%) 108 (23%)
Site of metastases
    Bone only 113 (29%) 164 (37%) 80 (17%)
    Others 282 (71%) 281 (63%) 388 (83%)
Karnofsky performance score
    10 - 20, ECOG 4 2 (0.5%) 2 (0.4%) 32 (7%)
    30 - 40, ECOG 3 44 (11%) 56 (13%) 112 (24%)
    50 - 60, ECOG 2 163 (41%) 208 (47%) 140 (30%)
    70 - 80, ECOG 1 167 (42%) 152 (34%) 160 (34%)
    90 - 100, ECOG 0 19 (5%) 27 (6%) 23 (5%)
    Median 60 60 2
    Range 10 - 100 10 - 100 0 - 4
Table 6. Summary of Patient Characteristics From Two Previous Survival Prediction Investigations
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way to present medical information to patients and their 
families. It has been shown that survival curves are a po-
tentially powerful tool to communicate information about 
health and treatment outcomes [19]. Survival curves provide 
a graphic presentation of the risk of an outcome over time, 
as they include a large amount of information that is diffi cult 
to convey with numbers alone [20, 21]. Furthermore, use of 
survival curves avoids the problem of having to select the 
time points to present–this is important as such a selection 
has been shown to infl uence treatment choice [22]. Figure 
1 may be of help to clinicians when counseling on survival. 
There has been no study examining whether an accurate 
prediction of survival can improve actual clinical care, nor 
investigating if the models improve the decision making in 
the care of this group of patients. Future studies should also 
evaluate the inception criteria and defi ne common inception 
points for the accrual of patients in studies of advanced dis-
ease. Quality of life assessment including self-rated health 
may assist in the selection of homogeneous cohorts of pa-
tients with terminal cancer and fi ne-tune the prognostic mod-
els.
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